The U.S. Court of Appeals for the Federal Circuit has dismissed an appeal filed by Sarepta Therapeutics, Inc. against the Trustees of the University of Pennsylvania and Regenxbio Inc. The dismissal, which occurred on October 8, 2026, means that the legal dispute between these parties will not proceed further in the court system. This decision affects the companies involved, particularly Sarepta Therapeutics, which was seeking to challenge a prior ruling related to patent rights.
The case, identified as docket number 26-1071, stemmed from a previous decision made by the United States Patent and Trademark Office (USPTO) Patent Trial and Appeal Board. In that earlier ruling, the board had addressed issues surrounding the validity of certain patents. The outcome of this appeal was significant for Sarepta, as it could have implications for their business operations and intellectual property rights.
Sarepta Therapeutics is a biotechnology company focused on developing innovative treatments for rare diseases, particularly genetic disorders. The Trustees of the University of Pennsylvania, a prestigious educational institution, and Regenxbio Inc., a gene therapy company, were the appellees in this case. The dispute likely revolved around the ownership and validity of patents related to gene therapy technologies that are crucial for the development of new treatments.
This appeal reached the Federal Circuit after Sarepta Therapeutics expressed dissatisfaction with the Patent Trial and Appeal Board's decision. The Federal Circuit is known for handling patent-related cases, and its rulings can significantly impact the biotechnology and pharmaceutical industries.
In the ruling, the court stated, "The proceeding is DISMISSED under Fed. R. App. P. 42 (b)." This means that the court accepted the parties' agreement to dismiss the case, effectively ending the legal battle without further examination of the underlying patent issues. The court also noted that "each side shall bear their own costs," indicating that neither party would be required to pay the other's legal fees.
This dismissal is nonprecedential, meaning it does not set a legal precedent for future cases. However, it still holds importance for the parties involved, as it concludes the litigation and allows them to move forward without the uncertainty of an ongoing legal dispute.
The impact of this ruling is significant for Sarepta Therapeutics, as the company can now refocus its efforts on its research and development initiatives without the distraction of this legal challenge. For the University of Pennsylvania and Regenxbio, the dismissal reinforces their position regarding the patents in question, allowing them to continue their work in gene therapy without the threat of further litigation from Sarepta.
Going forward, the dismissal of this appeal may influence how other companies approach patent disputes in the biotechnology sector. It highlights the importance of reaching agreements outside of court, as both parties opted to dismiss the case rather than continue with potentially lengthy and costly litigation.
Details were not available in the court filing regarding the specific reasons for the dismissal or any further comments from the parties involved. However, the outcome suggests that both sides found it in their best interest to resolve the matter amicably.
As of now, it is unclear whether Sarepta Therapeutics plans to pursue any further legal action related to this case or if there are any related cases pending. The court filing did not provide information on any future appeals or ongoing disputes that may arise from this situation.